The Dutch Colorectal Cancer Group (DCCG) is a collaboration between medical disciplines that are relevant for the diagnosis and treatment of colorectal cancer (surgical oncology radiotherapy medical oncology pathology radiology gastroenterology).

  • English
  • Dutch
Huidig pad: Home » > Publications

CAIRO

- Koopman M, Antonini F, Douma J, Wals J, Honkoop AH, Erdkamp FLG, de Jong RS, Rodenburg CJ, Vreugdenhil G, Akkermans-Vogelaar JM, Punt CJA. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. Ann Oncol 2006;17:1523-8

- Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FLG, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJL, van Bochove A, Sinnige HAM, Creemers GJM, Tesselaar MET, Slee PHThJ, Werter MJBP, Mol L, Dalesio O, Punt CJA. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer, a Dutch Colorectal Cancer Group (DCCG) phase III study. Lancet 2007;370:135-42

- Seymour MT, Punt CJA. CAIRO and FOCUS. Lancet 2007;370:1904-5

- Koopman M, Muller EW, Punt CJA. Reversible Posterior Leukoencephalopathy Syndrome due to Bevacizumab. Dis Colon Rectum 2008;51:1425-6

- Punt CJA, Koopman M. Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer. J Clin Oncol 2008;26:1907-8

- Kweekel DM, Gelderblom H, van der Sraaten T, Antonini NF, Punt CJA, Guchelaar HJ. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer; a Dutch Colorectal Cancer Group Study. Br J Cancer 2008:99;275-282.

- Seymour MT, Punt CJA. Sequential chemotherapy for advanced colorectal cancer: should we ever start with a single cytotoxic agent? Current Colorectal Cancer Reports 2008;4:130-8

- Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier JW, Gelderblom H, Punt CJ, Guchelaar HJ. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer. 2008;99:1316-21.

- Mol L, Koopman M, Ottevanger PB, Punt CJ. A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer. Ann Oncol 2009 Jul 24. [Epub ahead of print]

- Kweekel DM, Antonini NF, Nortier JW, Punt CJ, Gelderblom H, Guchelaar HJ. Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. Br J Cancer 2009;101:357-62.

- Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer 2009;45:1935-49.

- Kweekel DM, Gelderblom H, Antonini NF, van der Straaten T, Nortier JW, Punt CJ, Guchelaar HJ. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer 2009;45:572-8

- Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH, Punt CJ. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 2009;45:1999-2006. 

- Koopman M, Seymour MT, Punt CJ. The CAIRO and FOCUS studies: which lesson is to be learned? Oncologist 2009;14:192-3.

- Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, Punt CJ, van Krieken JH. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266-73.

- Postma C, Koopman M, Buffart TE, Eijk PP, Carvalho B, Peters GJ, Ylstra B, van Krieken JH, Punt CJ, Meijer GA. DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Ann Oncol 2009;20:1048-56.

- Koopman, M, Punt CJ. Chemotherapy, which drugs and when. Eur J Cancer 2009;45(suppl.1):50-6

- van Iersel L, Koopman M, van de Velde C, Mol L, van Persijn van Meerten E, Hartgrink H, Kuppen P, Vahrmeijer A, Nortier J, Tollenaar R, Punt C, Gelderblom H. Management of isolated non-resectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol 2010;21:1662-7

- Pander J, Gelderblom H, van der Straaten T, Punt CJ, Guchelaar HJ. Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array'. Br J Cancer 2010;102:1791-92

- Mekenkamp LJM, Koopman M, Teerenstra S, van Krieken JHJM, Mol L, Nagtegaal ID, Punt CJA. Clinicopathological features and outcome in advanced colorectal patients with synchronous versus metachronous metastases. Br J Cancer 2010;103:159-64

- Deenen MJ, Tol J, Burylo AM, Doodeman V, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJA, Schellens JHM, Cats A. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011;17:4355-68

- De Bruijn MT, Raats DA, Tol J, Hinrichs J, Teerenstra S, Punt CJ, Rinkes IH, Kranenburg O. Combined KRAS and TP53 Mutation Status Is Not Predictive in CAPOX-treated Metastatic Colorectal Cancer. Anticancer Res 2011;31:1379-85

Terug naar top


Site navigatie

Terug naar top


The Dutch Colorectal Cancer Group (DCCG) is a collaboration between medical disciplines that are relevant for the diagnosis and treatment of colorectal cancer (surgical oncology radiotherapy medical oncology pathology radiology gastroenterology).